Yüklüyor......
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
BACKGROUND: Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). Systemic use of bevacizumab has been linked to a wide range of renal adverse effe...
Kaydedildi:
| Yayımlandı: | J Nephropathol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Society of Diabetic Nephropathy Prevention
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607973/ https://ncbi.nlm.nih.gov/pubmed/28975092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15171/jnp.2017.23 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|